CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 108 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $274,552 | -48.4% | 18,414 | -62.1% | 0.00% | – |
| Q2 2023 | $532,137 | -88.8% | 48,597 | -91.1% | 0.00% | -100.0% |
| Q1 2023 | $4,746,261 | +94.3% | 544,296 | +39.7% | 0.00% | +200.0% |
| Q4 2022 | $2,442,710 | +246.5% | 389,587 | +93.7% | 0.00% | – |
| Q3 2022 | $705,000 | -8.9% | 201,083 | -23.4% | 0.00% | -100.0% |
| Q2 2022 | $774,000 | +4452.9% | 262,404 | +4662.3% | 0.00% | – |
| Q1 2022 | $17,000 | -75.7% | 5,510 | -73.4% | 0.00% | – |
| Q4 2021 | $70,000 | +59.1% | 20,730 | +72.4% | 0.00% | – |
| Q3 2021 | $44,000 | +29.4% | 12,024 | +54.2% | 0.00% | – |
| Q2 2021 | $34,000 | 0.0% | 7,799 | +3.1% | 0.00% | – |
| Q1 2021 | $34,000 | -88.3% | 7,565 | -85.0% | 0.00% | – |
| Q4 2020 | $291,000 | +144.5% | 50,548 | +209.7% | 0.00% | – |
| Q3 2020 | $119,000 | -96.2% | 16,324 | -98.2% | 0.00% | -100.0% |
| Q2 2020 | $3,115,000 | +133.0% | 892,464 | -1.2% | 0.00% | +100.0% |
| Q1 2020 | $1,337,000 | -49.4% | 903,355 | -33.0% | 0.00% | -50.0% |
| Q4 2019 | $2,640,000 | -48.0% | 1,347,290 | +35.8% | 0.00% | -50.0% |
| Q3 2019 | $5,079,000 | +3.2% | 991,827 | +44.2% | 0.00% | 0.0% |
| Q2 2019 | $4,923,000 | +1757.7% | 687,635 | +3343.7% | 0.00% | – |
| Q1 2019 | $265,000 | +68.8% | 19,968 | +0.0% | 0.00% | – |
| Q4 2018 | $157,000 | -16.5% | 19,966 | +17.7% | 0.00% | – |
| Q3 2018 | $188,000 | +37.2% | 16,966 | +66.1% | 0.00% | – |
| Q2 2018 | $137,000 | +1041.7% | 10,215 | +1012.7% | 0.00% | – |
| Q1 2018 | $12,000 | – | 918 | +183.3% | 0.00% | – |
| Q1 2016 | $0 | -100.0% | 324 | -32.8% | 0.00% | – |
| Q4 2014 | $5,000 | – | 482 | +1020.9% | 0.00% | – |
| Q3 2014 | $0 | – | 43 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |